CN119343061A - 含有氨基酸组合的药物组合物和保健食品组合物及其在以组织中脂质蓄积为特征的疾病中的用途 - Google Patents

含有氨基酸组合的药物组合物和保健食品组合物及其在以组织中脂质蓄积为特征的疾病中的用途 Download PDF

Info

Publication number
CN119343061A
CN119343061A CN202380049301.0A CN202380049301A CN119343061A CN 119343061 A CN119343061 A CN 119343061A CN 202380049301 A CN202380049301 A CN 202380049301A CN 119343061 A CN119343061 A CN 119343061A
Authority
CN
China
Prior art keywords
pharmaceutically
solvate
acceptable salt
therapeutically
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380049301.0A
Other languages
English (en)
Chinese (zh)
Inventor
约瑟夫·玛利亚·德拉斯普廖尔
泽维尔·埃斯科特米罗
塞尔吉奥·克萨达巴斯克斯
荷西·曼纽尔·费尔南德斯-雷尔莱莫斯
乔迪·马伊内里斯佩尔塞克斯
胡里奥·卡洛斯·包丁卢克
安东尼·卡伊马里帕洛
弗兰塞斯克·普伊格罗斯拉维尼斯
安娜·卡斯特利斯诺博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Federation Of Biotechnology Network Research Centers
Euro Carter Foundation
Institut d'Investigació Biomèdica de Girona
Original Assignee
Federation Of Biotechnology Network Research Centers
Euro Carter Foundation
Institut d'Investigació Biomèdica de Girona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federation Of Biotechnology Network Research Centers, Euro Carter Foundation, Institut d'Investigació Biomèdica de Girona filed Critical Federation Of Biotechnology Network Research Centers
Publication of CN119343061A publication Critical patent/CN119343061A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
CN202380049301.0A 2022-04-25 2023-04-25 含有氨基酸组合的药物组合物和保健食品组合物及其在以组织中脂质蓄积为特征的疾病中的用途 Pending CN119343061A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22382390 2022-04-25
EP22382390.7 2022-04-25
PCT/EP2023/060827 WO2023208944A1 (en) 2022-04-25 2023-04-25 Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues

Publications (1)

Publication Number Publication Date
CN119343061A true CN119343061A (zh) 2025-01-21

Family

ID=81579974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380049301.0A Pending CN119343061A (zh) 2022-04-25 2023-04-25 含有氨基酸组合的药物组合物和保健食品组合物及其在以组织中脂质蓄积为特征的疾病中的用途

Country Status (7)

Country Link
US (1) US20250268855A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514147A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515358A (cg-RX-API-DMAC7.html)
CN (1) CN119343061A (cg-RX-API-DMAC7.html)
CA (1) CA3249636A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013203A (cg-RX-API-DMAC7.html)
WO (1) WO2023208944A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11246846B2 (en) * 2017-10-23 2022-02-15 Michael S. Tempesta Trisodium citrate compositions having enhanced uptake across digestive mucosa

Also Published As

Publication number Publication date
EP4514147A1 (en) 2025-03-05
MX2024013203A (es) 2025-02-10
CA3249636A1 (en) 2023-11-02
JP2025515358A (ja) 2025-05-14
WO2023208944A1 (en) 2023-11-02
US20250268855A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
Wang et al. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis
Han et al. Protective effects of tuna meat oligopeptides (TMOP) supplementation on hyperuricemia and associated renal inflammation mediated by gut microbiota
JP5176964B2 (ja) ジペプチジルペプチダーゼiv阻害剤
Sprong et al. Dietary cheese whey protein protects rats against mild dextran sulfate sodium–induced colitis: Role of mucin and microbiota
TWI667025B (zh) 治療肝臟疾病之方法
EP3159005A1 (en) Uric acid level lowering agent
CN117919232B (zh) 吲哚丙酸在治疗肝硬化以及免疫性肝损伤的应用
Wang et al. Hypocholesterolemic effect of emodin by simultaneous determination of in vitro and in vivo bile salts binding
WO2017010133A1 (ja) 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物
CN110099690B (zh) 适于非酒精性脂肪性肝病和/或非酒精性脂肪性肝炎和/或肝脂肪变性的治疗的复方制剂
Zhang et al. Conjugated linoleic acid (CLA) reduces intestinal fatty acid uptake and chylomicron formation in HFD-fed mice associated with the inhibition of DHHC7-mediated CD36 palmitoylation and the downstream ERK pathway
Ganai et al. Regression of fibrosis/cirrhosis by Glycine propionyl-l-carnitine treatment in d-Galactosamine induced chronic liver damage
Ye et al. Effects of pectic oligosaccharide on growth performance, organ indexes and intestinal health in broilers exposed to aflatoxin B1
JP2008214242A (ja) ペプチド
KR20190003405A (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
Kim et al. The effect of granulated collagen tripeptide on sarcopenia in aged mice compared with collagen tripeptide
US20250268855A1 (en) Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues
WO2024178621A1 (en) Use of compounds in preventing and/or treating obesity or nafld
KR20200021880A (ko) 신경근육질환의 예방 또는 치료용 약학적 조성물
Fang et al. Regulatory effect of Chinese Baijiu on gut microbiota and host metabolism
Al-Tikrity et al. Preparation of nitrile derivative and study its effect as a possible novel drug for diabetes
JP7291917B2 (ja) トリペプチドrprを含有する抗肥満薬並びに健康食品
US20230404953A1 (en) Compound for the reduction of white adipose tissue and the treatment of overweight and obesity
CN111032067A (zh) 用于治疗脂肪肝病的刺地榆提取物
Vesković The effects of betain and neuregulin-1 on tissue, cellular and molecular changes on in vivo and in vitro models ov nonalcoholic fatty liver disease and fibrosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination